|
Cell Genesys wanted to be the beginning of the end for cancer. The development-stage company's lead technology was its GVAX immunotherapy platform, which hoped to stimulate a patient's immune system to fight tumors. A GVAX vaccine was in late-stage clinical development as a treatment for prostate cancer and was being evaluated as a possible treatment for pancreatic cancer, leukemia, and myelodysplastic syndrome. The GVAX platform suffered a blow in 2008, however, when its prostate cancer vaccine failed in a key clinical trial. As a result, Cell Genesys halted development of the vaccine and began considering strategic alternatives. The following year Cell Genesys agreed to be acquired by BioSante Pharmaceuticals.
|
|
More
on
Cell Genesys, Inc.
| |
• |
Quote
|
|
| |
• |
SEC
|
|
|
| | | Contact Information | |
Address: |
500 Forbes Blvd.
South San Francisco, CA 94080
| | Phone: | 650-266-3000 | | Fax: | 650-266-3010 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 94.60 M | | Revenue Growth (1 yr): | 6753.00% | | Employees (2008): | 61 | | Employee Growth (1 yr): | (-79.80%) |
|
|
Key People
| | • |
Chairman and CEO:
Stephen A. (Steve) Sherwin
| | • |
SVP, CFO, and Secretary:
Sharon E. Tetlow
| | • |
SVP Corporate Development:
Robert H. Tidwell
|
|
|
